亮細胞子宮內膜癌

Uterine Clear Cell Carcinoma

亮細胞子宮內膜癌為一種細胞色淺，預後較壞的子宮內膜癌，佔全部子宮內膜癌的1-6％。多發生在年長的婦女，轉移多發生在骨盆腔、主動脈淋巴結、和遠端部分，少有腹部的轉移。此病患加以骨盆腔放射線治療可以減少骨盆腔病灶的復發，特別是對沒有執行完整分期手術的患者。對全腹部放射線治療是否有用？報告則不盡相同，無法下結論，但通常顯示無好處。化學治療對晚期或復發之患者有助益，對第Ⅰ期a通常不需要，第Ⅰ期b和第Ⅱ期的患者因仍有高比例的遠端轉移，仍宜予化學輔助治療。carboplatin、和paclitaxel，被認為是較理想的選擇。

Uterine clear cell carcinoma is an aggressive variant of endometrial carcinoma, accounting for 1-6% of cases and associated with a poor prognosis. This tumor may be more common in older women. Patient with clear cell carcinoma often experience recurrence in the pelvis, in para-aortic nodes and at distant sires, whereas they do not seem to have a high relapse in the abdomen. Pelvic irradiation significantly reduces the risk of pelvic recurrence, whereas literature data on whole-abdomen irradiation have reported conflicting, inconclusive and generally disappointing results. Patients with stage Ia clear cell carcinoma who have undergone comprehensive surgical staging have a low risk of relapse and do not need any further management, whereas patients with more advanced disease should undergo some form of adjuvant postoperative therapy. Carboplatin and paclitaxel combination appears to have efficacy in the treatment of women with clear cell endometrial cancer.